Cardiac metabolic remodelling in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Metabolic Medicine

Background:

• Chronic kidney disease (CKD) affects millions globally, with a higher risk of cardiovascular disease (CVD) and mortality compared to the general population.
• Left ventricular hypertrophy (LVH) is prevalent in CKD patients (>75%) and contributes significantly to mortality, especially sudden cardiac death.
• Cardiac complications in CKD stem from multifactorial causes including hemodynamic overload, uremic toxins, and ion imbalance.

Purpose of the Study:

• To investigate the role of myocardial metabolic remodeling in the development of cardiac complications in CKD.
• To explore the specific metabolic maladaptations characterizing uremic cardiomyopathy.
• To identify potential novel therapeutic targets for uremic cardiomyopathy by understanding cardiac metabolism in CKD.

Main Methods:

• Review and analysis of existing literature on cardiac complications in CKD.
• Examination of myocardial metabolic remodeling, including mitochondrial function, substrate utilization, and metabolic transporters.
• Assessment of insulin signaling pathways, specifically the phosphoinositide-3 kinase-AKT pathway, in the context of CKD.

Main Results:

• Uremic cardiomyopathy is characterized by widespread metabolic dysregulation within the heart.
• Key metabolic alterations include impaired mitochondrial function, altered substrate utilization, and changes in metabolic transporter expression.
• Dysfunctional insulin response and PI3K-AKT signaling contribute to impaired cardiac energetics in CKD.

Conclusions:

• Myocardial metabolic remodeling is a critical, yet often overlooked, factor in the pathogenesis of uremic cardiomyopathy.
• Current CKD treatments do not directly address the metabolic derangements in the uraemic heart.
• Understanding these metabolic perturbations offers a promising avenue for developing novel treatments for uremic cardiomyopathy.